Abstract
This article informs the reader about the nature and extent of the economic burden of asthma and describes the literature on the cost-effectiveness of many of the major treatment choices for asthma. The author concludes that despite the many shortcomings, economic evaluations of asthma treatments need to be encouraged and nurtured. Substantial improvements and standardization are needed in the study design, study duration, sample size determination based on economic and health status end points, selection of appropriate comparison therapies, and selection and evaluation of costs and outcomes.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call